Giora Davidovits, Director, Chief Executive Officer, Chief Financial Officer,
President, Secretary, and Treasurer
Mr. Davidovits is currently our Chief Executive Officer, Chief Financial Officer,
President, Secretary Treasurer and a director of our company. Mr. Davidovits
brings 25 years of management experience at Fortune 500 companies to our company,
including Procter & Gamble, Johnson & Johnson, Abbott Laboratories,
and Rorer Consumer Pharmaceuticals, and of research experience at Ortho Diagnostics.
He is the President and a senior partner of CorInsight LLC, a marketing, business
development and technology transfer consultancy, and the past Chief Executive
Officer of ABC Diabetes, Inc.
Mr. Davidovits has a BA in biochemistry from Brandies University and an MBA
from Cornell University.
Mr. Davidovits introduced and successfully launched many products either in
the role of marketing executive or consultant. His healthcare experience includes
diabetes, cancer, pregnancy, cardiology, nephrology, podiatry, HIV, nutrition,
and multiple OTC categories.
We believe Mr. Davidovits is qualified to serve on our board of directors because
of his education and business experiences, including his experience as a director
of similar companies, as described above.
David Eyal Davidovits, Director, Vice President Business Development and Chief
Operating Officer
Mr. Davidovits brings 20 years of marketing, finance, and operations executive
experience at Intel, Marvell, and CorInsight. Mr. Davidovits was the Vice President
of Business Development of our company since April 5, 2012. His experience includes
assessments of strategic partnerships and joint ventures with Intel Capital,
Intel Haifa computer mobility group operations, finance management at Intel
USA, and the development of and responsibility for major Fortune 500 company
accounts at CorInsight. Mr. Davidovits is a senior partner of CorInsight LLC,
a marketing, business development and technology transfer consultancy, and General
Manager of CorInsights Israel office.
Mr. Davidovits has a BS in Manufacturing Engineering and Business Studies from
Coventry University, UK.
We believe Mr. Davidovits is qualified to serve on our board of directors because
of his education and business experiences, including his experience as a director
of similar companies, as described above.
Irit Arbel, Executive Vice President, Research and Development
Irit Arbel brings 15 years of management experience in the areas of cell therapy,
medical devices, and pharmaceuticals. She is a co-founder and served as chairperson
of several medical device companies including Real Aesthetics Inc. and BRH Medical.
She is a member of the RFB Investment House management team, and the co-founder
and board member at Brainstorm Cell Therapeutics. She served as CEO of Pluristem
Therapeutics and was Israels national sales manager for Merck, Sharp and Dohme
Ltd. Irit has extensive experience leading companies from startup to exits.
She was a post doctorate at Hadassah Hospital Neurological Department.
Ms. Arbel was a post doctorate at Hadassah Hospital Neurological Department.
Irit received a Doctor of Science (D.Sc.) in Neurology from The Technion Medical
School; MA in Medical Science; and BA in Chemical Engineering and Biology. Her
healthcare experience includes Alzheimer’s, MS, ALS, cancer, stem cell
therapy, cardiology, ophthalmology, and diabetic wound healing.
Benjamin Cherniak, Director
Mr. Cherniak is a director of our company. Since 2007, Mr. Cherniak has also
served as President for various companies engaged in the dissemination of sports
information relevant to the North American professional and collegiate leagues.
In these capacities, Mr. Cherniak’s responsibilities have included international
business development and the overseeing of all business operations of the various
companies. From 2003 to 2006, Mr. Cherniak was a principal with Bosworth Field
Associates and in 2007 Mr. Cherniak was a principal of Stanton Chase International.
Bosworth and Stanton are two executive recruiting firms, specializing in the
finance and accounting sectors. Previously, Mr. Cherniak has significant experience
in a wide array of businesses, specializing in the areas of marketing and product
development.
We believe Mr. Cherniak is qualified to serve on our board of directors because
of his education and varied business experiences, including his experience as
our director, as described above.
Odonate Therapeutics Inc currently has 10 employees.
